

## Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1. (Currently Amended) A composition consisting essentially of one or more standard doses of a hepatotoxic compound in a pharmaceutically acceptable carrier, ~~and the composition further comprising~~ about 5 mg to about 500 mg methionine per standard dose and about 10 mg to about 500 mg nicotinamide per standard dose as used in treatment of human disease.
2. (Original) The composition of claim 1 wherein said composition is suitable for oral ingestion.
3. (Original) The composition of claim 2 wherein said composition is selected from the group consisting of solutions, suspensions, tablets, capsules and caplets.
4. (Cancelled)
5. (Currently Amended) The composition of claim ~~[[4]]~~3 wherein said composition is selected from the group consisting of sterile solutions or suspensions.
6. (Original) The composition of claim 5 wherein said composition is suitable for intradermal, subcutaneous, intramuscular, intravenous or intrathecal injection.
7. (Currently Amended) The composition of claim 1 wherein ~~said composition also contains~~ folic acid is also present in an amount of about 50 mcg to about 5 mg per standard dose.
8. (Original) The composition of claim 7 wherein said composition is suitable for oral ingestion.
9. (Original) The composition of claim 8 wherein said composition is selected from the group consisting of solutions, suspensions, tablets, capsules and caplets.
10. (Cancelled)
11. (Currently Amended) The composition of claim ~~409~~9 wherein said composition is selected from the group consisting of sterile solutions or suspensions.
12. (Original) The composition of claim 11 wherein said composition is suitable for intradermal, subcutaneous, intramuscular, intravenous, or intrathecal injection.

13. (Currently Amended) ~~The composition of claim 1~~ A composition consisting essentially of one or more standard doses of a hepatotoxic compound, wherein said hepatotoxic compound is selected from the group consisting of acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, and valproic acid, in a pharmaceutically acceptable carrier, and about 5 mg to about 500 mg methionine per standard dose and about 10 mg to about 500 mg nicotinamide per standard dose as used in treatment of human disease.

14. (Original) The composition of claim 13 wherein said hepatotoxic compound is acetaminophen.

15. (Original) The composition of claim 14 wherein said acetaminophen is present in the amount of about 80-1000 mg per standard dose.

16. (Original) The composition of claim 13 wherein said hepatotoxic compound is methotrexate.

17. (Previously Presented) The composition of claim 16 wherein said methotrexate is present in the amount of about 2.5-250 mg per standard dose.

18. (Withdrawn) The composition of claim 13 wherein said hepatotoxic compound is atorvastatin.

19. (Withdrawn) The composition of claim 18 wherein said atorvastatin is present in the amount of about 5-100 mg per standard dose per standard dose.

20. (Withdrawn) The composition of claim 13 wherein said hepatotoxic compound is simvastatin.

21. (Withdrawn) The composition of claim 20 wherein said simvastatin is present in the amount of about 5-100 mg per standard dose.

22. (Withdrawn) The composition of claim 13 wherein said hepatotoxic compound is niacin.

23. (Withdrawn) The composition of claim 22 wherein said niacin is present in the amount of about 250-1000 mg per standard dose.

24. (Cancelled)

25. (Withdrawn) The composition of claim 24 wherein said flucanazole is present in the amount of about 10-250 mg per standard dose.

26. (Withdrawn) The composition of claim 13 wherein said hepatotoxic compound is divalproex sodium.

27. (Withdrawn) The composition of claim 26 wherein said divalproex sodium is present in the amount of 100-750 mg per standard dose.

28. (Withdrawn) The composition of claim 13 wherein said hepatotoxic compound is valproic acid.

29. (Withdrawn) The composition of claim 28 wherein said valproic acid is present in the amount of 25-500 mg per standard dose.

30. (Previously Presented) A method of mitigating the hepatotoxicity of a hepatotoxic compound comprising formulating a composition comprising a quantity of the hepatotoxic compound, said composition comprising a quantity of nicotinamide, and a quantity of methionine, as in claim 1.

31. (Withdrawn) The method of claim 30 wherein said composition is formulated such that for each standard dose of the hepatotoxic compound in the composition, the nicotinamide is present in the amount of about 5-500 mg, and the methionine is present in the amount of about 25-500 mg.

32. (Withdrawn) The method of claim 31 wherein said nicotinamide is present in the amount of about 25-200 mg per standard dose of the hepatotoxic compound.

33. (Withdrawn) The method of claim 31 wherein said methionine is present in the amount of about 10-100 mg per standard dose of the hepatotoxic compound.

34. (Withdrawn) The method of claim 30 wherein said composition further comprises a quantity of folic acid.

35. (Withdrawn) The method of claim 34 wherein said folic acid is present in the amount of about 50 mcg - 5 mg per standard dose of the hepatotoxic compound.

36. (Withdrawn) The method of claim 35 wherein said folic acid is present in the amount of about 00 mg - 1 mg per standard dose of the hepatotoxic compound.

37. (Withdrawn) The method of claim 30 wherein said hepatotoxic compound is selected from the group consisting of acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanazole, divalproex sodium, and valproic acid.